Our recent studies in pancreatic cancer identified for the first time that small molecules developed as selective mutant-IDH1 inhibitors [25–28], actually inhibit wtIDH1 with a high degree of potency under conditions present in the tumor microenvironment [24]. Here, IDH1 is linked to neoplasm.